Cargando…

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients

Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visualize and characterize tumor lesions. Additionally, it can be used to identify patients who may benefit from a particular therapy and monitor the therapy outcome. In recent years the field is focused...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Watering, Floor C. J., Rijpkema, Mark, Perk, Lars, Brinkmann, Ulrich, Oyen, Wim J. G., Boerman, Otto C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058511/ https://www.ncbi.nlm.nih.gov/pubmed/24991539 http://dx.doi.org/10.1155/2014/203601

Ejemplares similares

Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

In Vitro and In Vivo Characterization of (89)Zirconium-Labeled Lintuzumab Molecule
por: Allen, Kevin J. H., et al.
Publicado: (2022)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
por: Perk, Lars R., et al.
Publicado: (2009)

Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with (111)In in HEPES and MES buffer
por: Brom, Maarten, et al.
Publicado: (2012)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
por: Laban, Kamil G., et al.
Publicado: (2019)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016)

Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe
por: Ahmed, Mona, et al.
Publicado: (2020)

Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018)

The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021)

(68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET
por: Brom, Maarten, et al.
Publicado: (2010)

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89
por: Bhatt, Nikunj B., et al.
Publicado: (2017)

Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development
por: Pandya, Darpan N., et al.
Publicado: (2017)

In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2015)

Antibody therapy in renal cell carcinoma
por: Oosterwijk, Egbert, et al.
Publicado: (2008)

Radiolabeled antibodies in renal cell carcinoma
por: Stillebroer, Alexander B., et al.
Publicado: (2007)

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
por: Jagoda, Elaine M., et al.
Publicado: (2019)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
por: Mostafa, Ahmed M. A., et al.
Publicado: (2023)

Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice
por: Migotto, Mary-Anne, et al.
Publicado: (2019)

Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe
por: Heuveling, Derrek A., et al.
Publicado: (2018)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor
por: Rudd, Stacey E., et al.
Publicado: (2021)

Nuclear medicine imaging and therapy of neuroendocrine tumours
por: Gotthardt, Martin, et al.
Publicado: (2006)

Optimized labeling of NOTA-conjugated octreotide with F-18
por: Laverman, Peter, et al.
Publicado: (2011)

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
por: Roy, Jyoti, et al.
Publicado: (2021)

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach
por: Even, Aniek J.G., et al.
Publicado: (2016)

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®
por: Liapis, Vasilios, et al.
Publicado: (2020)

Radiolabelled peptides for oncological diagnosis
por: Laverman, Peter, et al.
Publicado: (2012)

PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides
por: Dijkgraaf, Ingrid, et al.
Publicado: (2010)

(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
por: Al-Zubaidi, Mohammed, et al.
Publicado: (2022)

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients
por: Bruijnen, Stefan, et al.
Publicado: (2016)

Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study
por: Hekman, Marlène C., et al.
Publicado: (2018)

A new technique for the radiolabelling of mixed leukocytes with zirconium‐89 for inflammation imaging with positron emission tomography
por: Fairclough, M., et al.
Publicado: (2016)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors
por: Beckford Vera, Denis R., et al.
Publicado: (2018)

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution
por: Larenkov, Anton, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p9324mm06fq3nunvsrbtqob6he